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The ageing of societies around the world, particularly 
in the European Union (EU), while to be celebrated, 
is associated with many challenges, most important of 
which is the provision of appropriate and timely pub-
lic health measures to address the growing number of 
older adults. As resources are limited, the relatively new 
construct of frailty has proved helpful in rationalising 
health expenditure and understanding which subgroup 
of older adults to target. Frailty is a multi-factorial 
state, correlating with vulnerability, disability and co-
morbidity resulting in an increased risk of adverse out-
comes and lower self-reported health status, for which 
no definition is broadly accepted so far. Older people 
are at greatest risk of becoming frail and developing 
disability. This poses crucial challenges to the well-
being of individuals and families, and to the sustain-
ability of health and social care systems. Since frailty 
is a dynamic condition along a continuum from normal 
ageing to disability, during which transitions between 
frailty states are common, and recovery, although not 
frequent, is possible, there is ample potential for pre-
vention and management. Based on these concepts the 
European Joint Action (JA) ADVANTAGE (http://ad-
vantageja.eu/), co-funded through the Third European 
Health Programme (grant number 724099), aims to 
develop a holistic and comprehensive strategic frame-
work for the prevention and management of frailty at 
European level, bringing together 33 partners from 22 
Member States. Understanding the current epidemiol-
ogy of frailty and the main measures to address it at 
population-level is one of the main steps undertaken by 
ADVANTAGE towards the development of a common 
Frailty Prevention Approach across Europe. 
Describing the real burden of frailty at population 
level, its frequency, progression and characteristics, 
and knowing which approaches and interventions for 
the monitoring, surveillance and screening of frailty are 
available at population level are fundamental to develop 
and calibrate an adequate public health response, bal-
ancing available resources against individual and col-
lective needs. A clear epidemiological picture of frailty 
in the population is necessary to inform resource plan-
ning, to prioritise interventions for groups of people 
deemed at higher risk, and to evaluate the effectiveness 
of prevention programmes.
What is the frequency of frailty in Europe? How many 
cases can we expect in the future? What are the charac-
teristics associated with the progression (or regression) 
of frailty? Who is more likely to develop higher or lower 
levels of frailty over time? Is the epidemiological picture 
of frailty well delineated and reliable? Is there evidence 
to support the adoption of public health measures to 
detect, prevent and manage frailty at population level? 
Do we have information on the efficacy and feasibil-
ity of public health interventions aimed at screening, 
monitoring or surveillance of frailty at population level, 
especially in primary care settings? These are the main 
research questions forming the basis of the systematic 
reviews of the scientific and grey literature conducted 
by Work Package 5 of the ADVANTAGE JA Knowing 
Frailty at Population Level, which are described in this 
monograph on the epidemiology of frailty. The four pa-
pers report the current state of the art relating to frailty 
prevalence [1], incidence [2], trajectories and transi-
tions over time [3], and screening, monitoring and sur-
veillance approaches for frailty [4]. The larger amount 
of papers selected through the review of prevalence sci-
entific literature allowed for the conduction of a meta-
analysis to provide an overall quantitative estimate of 
the parameter. Whereas the limited number and uneven 
characteristics of findings retrieved through the other 
literature reviews prevented from pooling and meta-an-
alysing results, which were synthesised and compared 
using a narrative and tabular approach.
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For the purpose of these systematic reviews the frailty 
parameters and interventions investigated were defined 
as follows.
Prevalence: the proportion of cases in a population in 
a specific moment (point prevalence) or over a specific 
period of time (period prevalence).
Incidence: the number of new cases of frailty per pop-
ulation in a given time period.
Trajectories: the clusters of individuals following a 
similar progression of frailty over time and Transitions: 
the changes between different stages of frailty over time 
(i.e. transition from robust, pre-frail, frail, and back).
Screening: systems, programmes, processes and in-
terventions specifically designed to identify frailty in a 
target population, in order to intervene to mitigate or 
reduce it at population level.
Surveillance: a systematic process for the collection, 
analysis and interpretation of health-related data on 
frailty, needed for the planning, implementation, and 
evaluation of public health interventions.
Monitoring: the process of observing for longitudinal 
changes in the health status (frailty) of a population; al-
though related to surveillance, monitoring is not neces-
sarily the trigger for a specific public health action and 
it can serve to measure the effect of an intervention on 
the health status of a population over time.
The first article of the series reviews the literature and 
provides a meta-analysis of the data on the prevalence 
of frailty in the 22 European countries involved in the 
JA ADVANTAGE [1]. The 62 papers reviewed and in-
cluded in the meta-analysis, representing 68 unique da-
tasets, showed a considerable and significant heteroge-
neity of results, with prevalence rates that varied greatly 
(median 10.8%) according to the classification of frail-
ty, the setting and the characteristics of participants, 
highlighting the need for a common and standardised 
approach to provide accurate and comparable frailty 
prevalence estimates at population level. The few stud-
ies retrieved through the systematic review of literature 
on frailty incidence (a total of 6 studies found, only 3 
of them conducted in Europe) [2] also showed consid-
erable heterogeneity of findings (incidence proportion 
range 5%-13%) with very different follow-up times and 
age of participants, and a substantial lack of analysis of 
those factors, such as basic socio-demographic charac-
teristics, potentially influencing the development of new 
cases of frailty. The adoption of incidence proportions 
(or cumulative incidence), rather than incidence rates, 
highly influenced by the duration of follow-up, was a 
further obstacle to comparing results. The systematic 
review of the literature on frailty trajectories and transi-
tions states over time [3] was focused on studies con-
ducted in Member States participating in the European 
JA ADVANTAGE. Again, results were very limited 
(only 3 studies included) and heterogeneous (1 study re-
porting trajectories and 2 providing data on transitions 
between different frailty states). Both papers reporting 
transitions provided the proportion of participants with 
at least one frailty transition during the period of follow-
up (34.3% over 2 years vs 32.6% over a double period 
of follow-up). The fourth and last paper of this mono-
graph reports the results of three systematic reviews of 
the scientific literature on programmes or interventions 
for the screening, monitoring and surveillance of frailty 
at population level, accompanied by an opportunistic 
review of the grey literature among ADVANTAGE JA 
Member States [4]. No systematic description of frailty 
surveillance programmes was retrieved. Only one study 
described monitoring systems and a few local examples 
of population screening initiatives (some of which not 
yet evaluated) were found. This highlights that there 
is insufficient evidence for the effectiveness of popu-
lation-level approaches to screening, monitoring and 
surveillance of frailty, suggesting the need for the devel-
opment and evaluation of community-based, two-step 
programmes including those that incorporate electronic 
health records, particularly in primary care.
The main feature of the epidemiological picture that 
emerges from the systematic reviews conducted by 
Work Package 5 of the ADVANTAGE JA is the overall 
heterogeneity of data on the frequency of frailty in the 
population. Nevertheless, frailty appears very common 
among older people, with an overall pooled estimated 
prevalence of 18% that varies according to the adopted 
classification of frailty and by study setting (about four 
times higher in hospital/nursing home settings than in 
the community). Although frailty is a dynamic condi-
tion that can be potentially reversed through appropri-
ate and timely intervention, there is a remarkable pauci-
ty of information about its progression over time, both 
in terms of the number of new cases per population in 
a given time period (incidence) and of the longitudinal 
changes among different levels of severity (transitions/
trajectories). The evidence for the feasibility, acceptabil-
ity, costs and potential benefits of screening strategies 
to address frailty are also very limited and are almost 
or totally lacking for monitoring or surveillance pro-
grammes. Few papers reported data from primary care. 
Further methodologically sound research is needed 
to provide standardised and comparable estimates of 
the occurrence and progression of frailty, and to scale-
up and assess public health interventions to address 
frailty. A careful longitudinal investigation of the major 
health and socioeconomic factors potentially involved 
in the development of new cases, and in the progression 
of existing ones, is of utmost importance to understand 
the underlying causes of frailty in the population and, 
if possible, to reverse it. There is a need to pilot and 
evaluate new programmes for the screening, monitoring 
and surveillance of frailty and to scale-up these across 
different countries. All these elements are essential to 
provide health care planners and policy makers with the 
evidence base to assist in the organisation and prioriti-
sation of public health services and programmes to tar-
get the most vulnerable groups of older people, ideally 
before the onset of functional decline. 
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